ABSTRACT
Since osteoporosis in men is more often secondary rather than primary (idiopathic), we need to seek the underlying cause through the history and laboratory testing. Treatment options are similar to those for women, although data are limited about their efficacy in men.
Footnotes
↵* The author has indicated that he has received grant or research support from Merck, Lilly, Pfizer, Aventis, Wyeth Ayerst, and Novartis corporations. This paper discusses treatment that is not approved by the US Food and Drug Administration for the use under discussion.
- Copyright © 2003 The Cleveland Clinic Foundation. All Rights Reserved.